Abstract
Immunotherapy against amyloid-β(Aβ) may improve rodent cognitive function by reducing amyloid neuropathology and is being validated in clinical trials with positive preliminary results. However, for a complete understanding of the direct and long-term immunization responses in the aged patient, and also to avoid significant side effects, several key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and Th2 responses in the elderly, and the reverse inflammatory events not found in the immunized rodent, better Alzheimer’s disease (AD) models are required. In the aged familiar canine with a Cognitive Dysfunction Syndrome (CDS) we describe the rapid effectiveness and the full safety profile of a new active vaccine candidate for human AD prevention and treatment. In these aged animals, besidesa weak immune system, the antibody response activated a coordinated central and peripheral Aβ clearance, that rapidly improved their cognitive function in absence of any side effects. Our results also confirm the interest to use familiar dogs to develop innovative and reliable therapies for AD.
Keywords: Aβ, Alzheimer’s disease, amyloid vaccine, canine cognitive dysfunction syndrome, immunotherapy, dog.
Current Alzheimer Research
Title:Rapid Improvement of Canine Cognitive Dysfunction with Immunotherapy designed for Alzheimer's Disease
Volume: 10 Issue: 5
Author(s): Maria Neus Bosch, Javier Gimeno- Bayon, Manuel J Rodriguez, Marco Pugliese and Nicole Mahy
Affiliation:
Keywords: Aβ, Alzheimer’s disease, amyloid vaccine, canine cognitive dysfunction syndrome, immunotherapy, dog.
Abstract: Immunotherapy against amyloid-β(Aβ) may improve rodent cognitive function by reducing amyloid neuropathology and is being validated in clinical trials with positive preliminary results. However, for a complete understanding of the direct and long-term immunization responses in the aged patient, and also to avoid significant side effects, several key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and Th2 responses in the elderly, and the reverse inflammatory events not found in the immunized rodent, better Alzheimer’s disease (AD) models are required. In the aged familiar canine with a Cognitive Dysfunction Syndrome (CDS) we describe the rapid effectiveness and the full safety profile of a new active vaccine candidate for human AD prevention and treatment. In these aged animals, besidesa weak immune system, the antibody response activated a coordinated central and peripheral Aβ clearance, that rapidly improved their cognitive function in absence of any side effects. Our results also confirm the interest to use familiar dogs to develop innovative and reliable therapies for AD.
Export Options
About this article
Cite this article as:
Bosch Maria Neus, Bayon Javier Gimeno-, Rodriguez Manuel J, Pugliese Marco and Mahy Nicole, Rapid Improvement of Canine Cognitive Dysfunction with Immunotherapy designed for Alzheimer's Disease, Current Alzheimer Research 2013; 10 (5) . https://dx.doi.org/10.2174/15672050113109990129
DOI https://dx.doi.org/10.2174/15672050113109990129 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population
Current Alzheimer Research Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Current Pharmaceutical Design Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Mitigating Alzheimer’s Disease with Natural Polyphenols: A Review
Current Alzheimer Research Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Chronic Migraineurs Form Carboxyhemefibrinogen and Iron-Bound Fibrinogen
CNS & Neurological Disorders - Drug Targets